NDAORALSOLUTION
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
QUIOFIC (folic acid) by Teva is clinical pharmacology folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. First approved in 2026.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIOFIC (folic acid) is an oral solution vitamin B supplement that restores normal erythropoiesis by converting megaloblastic bone marrow to normoblastic marrow. It acts as a cofactor in nucleoprotein synthesis and DNA formation, treating folic acid deficiency and megaloblastic/macrocytic anemias. The drug is absorbed rapidly from the small intestine with peak plasma levels achieved within 1 hour of oral administration.
Launch
As a newly approved (2026) oral solution from Teva, this product enters a mature vitamin market with moderate competitive pressure (30%), likely requiring focused commercial execution and specialized field teams.
Mechanism of Action
CLINICAL PHARMACOLOGY Folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as…
Worked on QUIOFIC at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.